Latest Bellevue Group AG Stock Portfolio
Bellevue Group AG Performance:
2024 Q3: 2.26%YTD: 4.05%2023: 1.05%
Performance for 2024 Q3 is 2.26%, and YTD is 4.05%, and 2023 is 1.05%.
About Bellevue Group AG and 13F Hedge Fund Stock Holdings
In it's latest 13F Holdings report, Bellevue Group AG reported an equity portfolio of $6.2 Billions as of 30 Sep, 2024.
The top stock holdings of Bellevue Group AG are , IONS, VRTX. The fund has invested 5.6% of it's portfolio in ARGENX SE and 5.1% of portfolio in IONIS PHARMACEUTICALS INC.
The fund managers got completely rid off SILK RD MED INC (SILK), ATRICURE INC (ATRC) and OUTSET MED INC (OM) stocks. They significantly reduced their stock positions in HUTCHMED CHINA LTD, APELLIS PHARMACEUTICALS INC (APLS) and CENTENE CORP DEL (CNC). Bellevue Group AG opened new stock positions in TERNS PHARMACEUTICALS INC (TERN), BRISTOL-MYERS SQUIBB CO (BMY) and SUMMIT THERAPEUTICS INC (SMMT). The fund showed a lot of confidence in some stocks as they added substantially to JOHNSON & JOHNSON (JNJ), BIOMARIN PHARMACEUTICAL INC (BMRN) and VIKING THERAPEUTICS INC (VKTX).
The top stock holdings of Bellevue Group AG are , IONS, VRTX. The fund has invested 5.6% of it's portfolio in ARGENX SE and 5.1% of portfolio in IONIS PHARMACEUTICALS INC.
The fund managers got completely rid off SILK RD MED INC (SILK), ATRICURE INC (ATRC) and OUTSET MED INC (OM) stocks. They significantly reduced their stock positions in HUTCHMED CHINA LTD, APELLIS PHARMACEUTICALS INC (APLS) and CENTENE CORP DEL (CNC). Bellevue Group AG opened new stock positions in TERNS PHARMACEUTICALS INC (TERN), BRISTOL-MYERS SQUIBB CO (BMY) and SUMMIT THERAPEUTICS INC (SMMT). The fund showed a lot of confidence in some stocks as they added substantially to JOHNSON & JOHNSON (JNJ), BIOMARIN PHARMACEUTICAL INC (BMRN) and VIKING THERAPEUTICS INC (VKTX).
Bellevue Group AG Annual Return Estimates Vs S&P 500
Our best estimate is that Bellevue Group AG made a return of 2.26% in the last quarter. In trailing 12 months, it's portfolio return was 15.3%.
New Buys
| Ticker | $ Bought |
|---|---|
| terns pharmaceuticals inc | 8,691,410 |
| bristol-myers squibb co | 1,905,330 |
| summit therapeutics inc | 1,403,660 |
| biontech se | 1,035,790 |
| sanofi | 870,732 |
| denali therapeutics inc | 457,341 |
| travere therapeutics inc | 433,690 |
| arcellx inc | 334,040 |
New stocks bought by Bellevue Group AG
Additions
| Ticker | % Inc. |
|---|---|
| johnson & johnson | 557 |
| biomarin pharmaceutical inc | 533 |
| viking therapeutics inc | 267 |
| beigene ltd | 129 |
| arcutis biotherapeutics inc | 125 |
| zoetis inc | 79.67 |
| evolent health inc | 59.9 |
| pfizer inc | 59.2 |
Additions to existing portfolio by Bellevue Group AG
Reductions
| Ticker | % Reduced |
|---|---|
| hutchmed china ltd | -97.91 |
| apellis pharmaceuticals inc | -95.71 |
| tempus ai inc | -89.68 |
| centene corp del | -79.43 |
| bio rad labs inc | -70.27 |
| charles riv labs intl inc | -68.58 |
| doximity inc | -59.73 |
| biogen inc | -55.37 |
Bellevue Group AG reduced stake in above stock
Sold off
| Ticker | $ Sold |
|---|---|
| silk rd med inc | -23,127,100 |
| outset med inc | -2,936,780 |
| teladoc health inc | -2,667,960 |
| atricure inc | -4,839,970 |
| nevro corp | -1,138,680 |
| c4 therapeutics inc | -266,112 |
| dynavax technologies corp | -309,476 |
| 89bio inc | -197,847 |
Bellevue Group AG got rid off the above stocks
Sector Distribution
Bellevue Group AG has about 90.9% of it's holdings in Healthcare sector.
| Sector | % |
|---|---|
| Healthcare | 90.9 |
| Others | 9 |
Market Cap. Distribution
Bellevue Group AG has about 53.4% of it's portfolio invested in the large-cap and mega-cap stocks.
| Category | % |
|---|---|
| LARGE-CAP | 49.5 |
| MID-CAP | 27.1 |
| UNALLOCATED | 9.4 |
| SMALL-CAP | 8.5 |
| MEGA-CAP | 3.9 |
| MICRO-CAP | 1.5 |
Stocks belong to which Index?
About 67.4% of the stocks held by Bellevue Group AG either belong to S&P 500 or RUSSELL 2000 index.
| Index | % |
|---|---|
| S&P 500 | 41.9 |
| Others | 32.5 |
| RUSSELL 2000 | 25.5 |
Bellevue Group AG Holdings Map
This heatmap illustrates the top 50 positions within the fund's portfolio.
Current Stock Holdings of Bellevue Group AG
Bellevue Group AG has 162 stocks in it's portfolio. About 39.2% of the portfolio is in top 10 stocks. MRNA proved to be the most loss making stock for the portfolio. CDNA was the most profitable stock for Bellevue Group AG last quarter.
Last Reported on: 14 Nov, 2024| Ticker | Namesorted ascending | % Portfolio | Shares Held | $ Value | Type | % Change | Options | |
|---|---|---|---|---|---|---|---|---|
| A | agilent technologies inc | 0.00 | 769 | 114,181 | added | 9.23 | ||
| AAPL | apple inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| ABBV | abbvie inc | 0.14 | 42,886 | 8,469,130 | added | 1.62 | ||
| ABC | cencora inc | 0.26 | 72,053 | 16,217,700 | reduced | -19.34 | ||
| ABT | abbott labs | 3.22 | 1,743,940 | 198,826,000 | added | 8.58 | ||
| ACCD | accolade inc | 0.04 | 640,865 | 2,467,330 | reduced | -23.94 | ||
| ACLX | arcellx inc | 0.00 | 4,000 | 334,040 | new | |||
| ADMA | adma biologics inc | 0.01 | 25,900 | 517,741 | reduced | -16.18 | ||
| AGIO | agios pharmaceuticals inc | 2.69 | 3,735,920 | 165,987,000 | reduced | -3.7 | ||
| ALGN | align technology inc | 0.59 | 143,996 | 36,621,100 | added | 0.01 | ||
| ALKS | alkermes plc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| ALNY | alnylam pharmaceuticals inc | 3.60 | 809,095 | 222,525,000 | reduced | -12.04 | ||
| ALT | altimmune inc | 0.09 | 863,660 | 5,302,870 | added | 43.94 | ||
| AMEH | astrana health inc | 0.24 | 254,182 | 14,727,300 | added | 1.42 | ||
| AMGN | amgen inc | 0.13 | 25,152 | 8,104,230 | reduced | -14.82 | ||
| AMRX | amneal pharmaceuticals inc | 0.01 | 76,414 | 635,764 | added | 21.76 | ||
| ANNX | annexon inc | 0.50 | 5,157,290 | 30,531,200 | unchanged | 0.00 | ||
| APLS | apellis pharmaceuticals inc | 0.01 | 19,046 | 549,287 | reduced | -95.71 | ||
| ARQT | arcutis biotherapeutics inc | 0.01 | 39,500 | 367,350 | added | 125 | ||
| ARVN | arvinas inc | 0.95 | 2,386,600 | 58,782,000 | reduced | -0.18 | ||